Sedation for Paediatric MRI
Phase 4
Completed
- Conditions
- Health Condition 1: null- children belonging to ASA status 1/2 undergoing MRI for diagnostic or therapeutic purpose
- Registration Number
- CTRI/2013/09/004031
- Lead Sponsor
- Department of Anaesthesia ESI PGIMSR
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ASA status 1 or2 patients in age gp 6 mths to 10 yrs for elective MRI
Exclusion Criteria
ASA status 3 or above, severe cardiovascular or pulmonary pathology;
documented allergy or intolerance to propofol ; anatomical anomaly of airway; tonsillar hypertrophy grade 3 or above; MRI for acute trauma.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie propofol and ketamine synergy in pediatric sedation for MRI?
How does propofol infusion after low-dose ketamine compare to standard sedation protocols in ambulatory pediatric MRI?
Are there specific biomarkers that predict sedation response to propofol-ketamine combination in children with ASA status 1/2?
What are the known adverse events and management strategies for propofol-ketamine sedation in pediatric MRI?
What alternative sedation regimens or competitor drugs are being evaluated for pediatric MRI procedures in clinical trials?